CLIA Kit for Fibulin 3 (FBLN3) Homo sapiens (Human) Sandwich CLIA

EFEMP1; DHRD; DRAD; FBNL; MLVT; MTLV; S1-5; EGF-Containing Fibulin-Like Extracellular Matrix Protein 1; Fibrillin-Like; Extracellular protein S1-5

Add to Cart Distributors
Overview
Properties
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • CLIA Kit for Fibulin 3 (FBLN3) Packages (Simulation)
  • CLIA Kit for Fibulin 3 (FBLN3) Packages (Simulation)
  • CLIA Kit for Fibulin 3 (FBLN3) Results demonstration
  • SCF422Hu.jpg Typical Standard Curve
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Recovery

Matrices listed below were spiked with certain level of recombinant Fibulin 3 (FBLN3) and the recovery rates were calculated by comparing the measured value to the expected amount of Fibulin 3 (FBLN3) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 96-105 101
EDTA plasma(n=5) 98-105 102
heparin plasma(n=5) 86-101 91

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Fibulin 3 (FBLN3) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Fibulin 3 (FBLN3) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Fibulin 3 (FBLN3) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 79-95% 98-105% 90-101% 86-97%
EDTA plasma(n=5) 91-99% 97-105% 88-102% 86-99%
heparin plasma(n=5) 80-101% 84-94% 98-105% 87-98%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
Pre-coated, ready to use 96-well strip plate 1 Plate sealer for 96 wells 4
Standard 2 Standard Diluent 1×20mL
Detection Reagent A 1×120µL Assay Diluent A 1×12mL
Detection Reagent B 1×120µL Assay Diluent B 1×12mL
Substrate A 1×10mL Substrate B 1×2mL
Wash Buffer (30 × concentrate) 1×20mL Instruction manual 1

Assay procedure summary

1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 100µL Substrate Solution. Incubate 10 minutes at 37°C;
8. Read RLU value immediately.

CLIA Kit for Fibulin 3 (FBLN3)

Test principle

The microplate provided in this kit has been pre-coated with an antibody specific to Fibulin 3 (FBLN3). Standards or samples are then added to the appropriate microplate wells with a biotin-conjugated antibody specific to Fibulin 3 (FBLN3). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. Then the mixture of substrate A and B is added to generate glow light emission kinetics. Upon plate development, the intensity of the emitted light is proportional to the Fibulin 3 (FBLN3) level in the sample or standard.;

Citations

  • Fibulin-3 as a Blood and Effusion Biomarker for Pleural MesotheliomaPubMed: PMC3761217
  • YKL-40 and mesothelin in the blood of patients with malignant mesothelioma, lung cancer and asbestosis.Pubmed: 24324091
  • Role of fibulin-3 in lung cancer: In vivo and in vitro analysesSpandidos-publications: Source
  • Discovery of new biomarkers for malignant mesotheliomaSpringer:Source
  • DIAGNOSIS OF CELL PROLIFERATIVE DISEASESFreepatentsonline:Source
  • Comparison of fibulin-3 and mesothelin as markers in malignant mesotheliomaPubmed:Pmc4174124
  • Value of plasma and pleural effusion fibulin-3 levels in the diagnosis of malignant pleural mesothelioma effusionsPubmed:23050525
  • Fibulin-3 as a biomarker of response to treatment in malignant mesotheliomaPubMed: 26401134
  • Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosisPubMed: 26263483
  • Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma.Pubmed:26903362
  • Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational study pubmed:27884852
  • HMGB1 and its hyperacetylated isoform are sensitive and specific serum biomarkers to detect asbestos exposure and to identify mesothelioma patientspubmed:26733616
  • Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational …e013324.abstract
  • Comparison of the Diagnostic Performance of Fibulin-3 and Mesothelin in Patients with Pleural Effusions from Malignant Mesothelioma.pubmed:28314308
  • A Novel Panel of Serum Biomarkers for MPM Diagnosis.pubmed:28348450
  • Association of fibulin-3 concentrations with the presence and severity of knee osteoarthritis: A cross-sectional studypubmed:29195846
  • Plasma Fibulin-3 as a Potential Biomarker for Patients with Asbestos-Related Diseases in the Han Populationpubmed:29200597
  • Placental protein 14 as a potential biomarker for diagnosis of preterm premature rupture of membranesPubmed:29749501
  • The matrix protein Fibulin-3 promotes KISS1R induced triple negative breast cancer cell invasionPubmed:30046386
  • Fibulin-3 and other cartilage metabolism biomarkers in relationship to calprotectin (MRP8/14) and disease activity in rheumatoid arthritis patients treated with …68362.pdf
  • Prediction of pneumoconiosis by serum and urinary biomarkers in workers exposed to asbestos-contaminated mineralsPubmed: 30946771

Recommend products